Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer

Jin-Liang Zhang, Min Liu, Qing Yang, Shi-Yong Lin, Hong-Bo Shan, Hui-Yun Wang, Guo-Liang Xu

AIM
To explore the effects of omeprazole on chemoradiotherapy efficacy and tumor recurrence in rectal cancer.

METHODS
The medical data of 125 rectal cancer patients who received the same neoadjuvant chemoradiotherapy (CRT) followed by surgery were retrospectively collected. Patients who received omeprazole (OME) orally at a dose of 20 mg at least once daily for six days and/or intravenously at 40 mg a day were recognized as eligible OME users (EOU). Otherwise, patients were regarded as non-eligible OME users (non-EOU).
INTRODUCTION

Rectal cancer is one of the worldwide leading causes of cancer related death\(^1\). Preoperative chemoradiotherapy (CRT) followed by radical surgery is a preferred treatment for patients with advanced rectal cancer for its reduced local recurrence and high sphincter preservation rate\(^2\). However, disease relapse is still a critical factor that affects patient survival\(^2\). The exploration of factors that affect CRT efficacy and tumor recurrence is important to improve cancer management.

Abnormal pH gradients in the tumor microenvironment are involved in tumorigenesis, tumor progression and drug resistance\(^3\)-\(^11\). Vacular type H\(+\)ATPases (V-ATPases) are proton pumps expressed on the membrane of endolysosomal organelles and plasma membranes\(^5\), which could modulate the tumor acidic microenvironment\(^12\)-\(^13\), V-ATPases are overexpressed in chemo-resistant cancer cells and are induced by cytotoxic drugs\(^14\)-\(^15\), playing a key role in cancer cells with a multidrug resistance phenotype\(^16\). Proton pump inhibitors (PPIs), such as omeprazole (OME) and esomeprazole, are used to relieve common side effects of chemotherapy, such as nausea and emesis. In addition to targeting the gastric acid pump, PPIs inhibit the activity of V-ATPases\(^17\)-\(^20\). Moreover, PPIs induce apoptosis in gastric cancer cells\(^21\), B-cell tumors\(^22\) and hepatoblastoma cells\(^23\) and promote autophagy in melanoma cells\(^24\) and pancreatic cancer cells\(^25\). PPIs improve the efficacy of T-cell-based cancer immunotherapy\(^26\)-\(^28\). In colorectal cancer, it is reported that PPIs re-sensitize drug-resistant cancer colon adenocarcinomas cell lines to cytotoxic drugs\(^28\)

These study results suggest that the application of PPIs may be helpful in improving cancer treatment. However, whether PPIs could affect CRT efficacy, reduce tumor recurrence and improve survival in rectal cancer patients remain unclear.

MATERIALS AND METHODS

Patients

From May 2008 to March 2016, the medical records of consecutive rectal cancer patients who received the same neoadjuvant CRT followed by radical surgery were retrospectively collected. Neoadjuvant CRT included three-dimensional conformal radiotherapy (3D-CRT) using a total dose of 46 Gy concurrent with two cycles of oxaliplatin plus capecitabine. The disease was diagnosed by a combination of medical history, physical examination, biopsy, and staging examination, including abdominal ultrasound, abdominal-pelvis computed tomography, colonoscopy and endoscopic or trans-rectal ultrasonography. Tumors were staged according to the AJCC (2010 edition). Tumor stages before CRT and after surgery were classified as cTNM and ypTNM, respectively. Patients lacking detailed medical records or those with a second tumor or distant metastasis were excluded. Finally 125 patients met the criteria. The patients were aged 15-78 years, with a mean age of 55.8 ± 12.01 years. The mean

Moreover, a preferred OME dose cut-off of 200 mg on tumor recurrence was obtained by receiver operating characteristic (ROC) curves. Patients were divided into two groups: the effective OME group (EOG, OME ≥ 200 mg) and the non-effective OME group (non-EOG, OME < 200 mg).

RESULTS

The good response rate of CRT efficacy (50.8%) in EOU was significantly increased compared with non-EOU (30.6%) \((P = 0.02)\). The recurrence rate in the EOG was 10.3%, which was significantly lower compared with 31.3% in non-EOG \((P = 0.025)\). The good response rate of CRT efficacy in EOG was 55.2%, which was obviously higher compared with 36.5% in non-EOG, with a significant difference \((P = 0.072)\). Multivariate Cox analysis demonstrated that OME (non-EOG and EOG) was an independent and significant impact factor for DFS \((P = 0.048, HR = 0.30, 95\% CI: 0.09-0.99)\).

CONCLUSION

When applied as an adjuvant drug in cancer treatment for relieving common side effects of chemotherapy, omeprazole has a synergetic effect in improving CRT efficacy and decreasing rectal cancer recurrence.

Key words: Omeprazole; Chemoradiotherapy efficacy; Recurrence; Rectal cancer

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In \textit{in vitro} and \textit{in vivo} studies, proton pump inhibitors (PPIs) induce apoptosis of gastric cancer cells, B-cell tumors and hepatoblastoma cells and promote autophagy in melanoma cells and pancreatic cancer cells. PPIs also sensitize chemo-resistant tumors to cytotoxic drugs and improve the efficacy of T-cell-based cancer immunotherapy. However, whether PPIs affect chemoradiotherapy (CRT) efficacy, decrease tumor recurrence and improve survival in rectal cancer patients remains unclear. In the present study, when used as adjuvant drug in cancer treatment, omeprazole has a synergetic effect in improving CRT efficacy and decreasing recurrences in rectal cancer.

Zhang JL, Liu M, Yang Q, Lin SY, Shan HB, Wang HY, Xu GL. Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World J Gastroenterol 2017; 23(14): 2575-2584 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i14/2575.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i14.2575
body weight and mean height of the patients was 60.1 ± 9.3 kg and 164.1 ± 6.85 cm, respectively. Pre-treatment serum carcinoembryonic antigen (CEA) and CA19-9 data were available in 120 of the 125 patients. The study was approved by the Medical Ethics Committee of Sun Yat-Sen University Cancer Center. Written informed consent was obtained from all patients.

Neoadjuvant concurrent CRT
Radiation treatment planning was designed according to the three-dimensional conformal radiation therapy (3D-CRT), with one posterior field and two lateral fields. Patients were treated using a range of 6-15 MV photons. Radiation was delivered at a total dose of 46 Gy (23 fractions with 2 Gy per fraction in 5 wk). Gross tumor volumes (GTVs) included rectal tumors and enlarged lymph nodes. Clinical target volumes (CTVs) included lymphatic drainage areas around the rectum and sacrum. Planning target volume (PTV) included areas with a 0.8-1.0 cm radial margin around the CTV. Patients were treated in the prone position, and a belly board was used to exclude the small bowel out of the radiation field. Oxaliplatin (130 mg/m²) was delivered intravenously over 2 h on the first day of radiation treatment and on day 21. Capecitabine was administered orally twice daily at 1000 mg/m² on days 1-14 and days 21-34.

Dosage of omeprazole
Omeprazole usage was recorded in detail. Omeprazole was administered orally at 20 mg twice a day (Omeprazole Magnesium Entericcoated Tablets, AstraZeneca AB), 40 mg (Omeprazole Sodium for Injection, AstraZeneca AB) or 60 mg (Omeprazole Sodium for Injection, Changzhou Siyao Pharmaceuticals Co., Ltd.) intravenously one hour before the start of chemotherapy and was continuously administered in the following days if the patients complained of digestive discomfort. The reduction in gastric peak acid secretion after continuous oral administration of 20 mg OME once daily for six days was comparable with the effect of a single intravenous dose of 40 mg OME[29]. Thus, patients who received 20 mg OME orally at least once a day for six days and/or intravenous infusion of 40 mg OME daily were recognized as eligible OME users (EOU); otherwise, the patients were regarded as non-eligible OME users (non-EOU). Among the 125 patients, 63 patients met the criteria as EOU. Moreover, the bioavailability of oral enteric-coated omeprazole granules was initially low (approximately 35%-40%); however, it increased to approximately 65% on repeated dosing[20-22]. Therefore, the oral dose of EOU was multiplied by 65% to convert to a dose comparable with the intravenous dose for the intention of equal drug bioavailability.

Surgery, tumor regression evaluation and adjuvant chemotherapy
Radical surgery was performed 4-6 wk after CRT completion. Primary tumor regression grade (TRG) was determined semiquantitatively according to a modified Dworak scale[31] based on the amount of viable tumor vs the amount of fibrosis as follows: 0, no regression; 1, dominant tumor mass with obvious fibrosis and/or vasculopathy; 2, dominantly fibrotic changes with few tumor cells or groups (easy to find); 3, very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without a mucous-like substance; and 4, no tumor cells and only fibrotic mass (total regression or response). A Dworak grade of 2 or 3 was determined by two experienced pathologists. CRT efficacy was classified as either a "good response" or a "poor response". Good response cases were those whose tumor regression was classified as TRG 0 or 4; poor response cases were those whose tumor regression was graded as TRG 1 or 2. Patients were advised to undergo four to six cycles of adjuvant chemotherapy that was the same as neoadjuvant chemotherapy 4-6 wk after surgery completion. When patients could not endure the side effects of adjuvant chemotherapy, capecitabine monotherapy was adopted. Finally, 125 patients received 479 cycles of adjuvant chemotherapy.

Follow-up
After completion of combined treatment, patients were followed up every 3 to 6 mo in the first 3 years and every 12 mo thereafter. Patient evaluation included a physical examination, abdominal ultrasonography or computed tomography scan, chest X-ray, and serum CEA and CA19-9 levels. Diagnosis of recurrence was based on two types of radiologic examination with or without abnormal plasma tumor markers. Histopathological verification was performed when necessary. The survival status was verified by examination of clinical attendance records and direct telecommunication with the patient or their family in March 2016. Survival was censored at the time of the last follow-up on March 1, 2016, with a median follow-up time of 66 mo (range 17-99 mo).

End points and statistical analysis
The study end points were CRT efficacy, recurrence, disease-free survival (DFS) and overall survival (OS). DFS was defined as the interval from surgery to either confirmed recurrence or death, and OS was defined as the time interval between surgery and death. Continuous variables were expressed as the mean ± SD. Student t test and χ² tests were used to compare differences between groups. A receiver operating characteristic (ROC) curve was plotted to identify a proper cut-off value. Kaplan-Meier analysis was used to compare survival using the log-rank test.
Univariate and multivariate Cox proportional hazard models were used to assess the effect of risk factors on survival. Forward conditional methods were used to establish the multivariate Cox proportional hazards model. A two-tailed $P$ value less than 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS statistical software package (version 22).

**RESULTS**

**Clinicopathological characteristics of patients treated at different doses of OME**

Among 63 OME users, 7 patients only received OME orally, 47 patients only received OME intravenously, and 9 patients received OME both orally and intravenously. The detailed information of OME dosage is presented in Table 1. The good response rate (50.8%) in the EOU was significantly increased compared with non-EOU ($P = 0.02$, OR = 2.336, 95%CI: 1.124-4.856). No significant differences for other clinicopathological factors were found between the EOU and non-EOU groups (all $P$ values > 0.05). The patient characteristics of EOU and non-EOU are summarized in Table 2.

PPIs inhibit cancer cell proliferation in a dose-dependent manner\(^{[25,35]}\). Therefore, in addition to arbitrarily applying a cut-off that meets the inclusion criterion, a preferred OME dose cut-off for tumor recurrence was investigated by ROC curves. The dose that was closest to the upper left corner (100% sensitivity and 100% specificity) was selected as the cut-off dose. The area under the ROC curve (AUC) was calculated to estimate the discriminatory power of the produced OME dose cut-off of the entire dose range on recurrence. A dose cut-off of 200 mg was identified by ROC as the optimized point that differentiated recurrence from non-recurrence with maximal sensitivity and specificity (Figure 1). The AUC was 0.66 ($P = 0.053$), and the OME dose of 200 mg differentiated recurrence from non-recurrence with a specificity of 82.4% and a sensitivity of 56.5%. Patients were then divided into the effective OME group (EOG, patients received OME $\geq 200$ mg) and non-effective OME group (non-EOG, patients received OME < 200 mg). Non-EOG and EOG patient characteristics are summarized in Table 3.

Univariate and multivariate Cox proportional hazard models were used to assess the effect of risk factors on survival. Forward conditional methods were used to establish the multivariate Cox proportional hazards model. A two-tailed $P$ value less than 0.05 was considered statistically significant. Statistical analysis was performed using the SPSS statistical software package (version 22).

**Table 1** Mean dose and duration of omeprazole administered orally and intravenously

| OME   | Cases | administered dose (mg) | OME administration (No. of days) |   |   |   |   |
|-------|-------|------------------------|----------------------------------|---|---|---|---|
|       |       | Mean ± SD              | 95%CI                            | Max | Min | Mean ± SD | 95%CI | Max | Min |
| Oral1 | 7     | 260.0 ± 143.2          | 127.6-392.4                      | 546 | 182 | 11.0 ± 8.0 | 3.6-18.3 | 28 | 7  |
| IV2   | 47    | 217.2 ± 184.8          | 162.8-271.3                      | 940 | 40  | 3.8 ± 3.0  | 2.9-4.6  | 16 | 1  |
| IV + Oral3 | 9   | 406.2 ± 184.9          | 264.1-548.4                      | 756 | 151 | 13.7 ± 7.0 | 8.2-19.1 | 28 | 7  |

1Oral OME multiplied by 65%; 2 OME received intravenously; 3 Oral OME multiplied by 65% plus OME received intravenously. OME: Omeprazole.

**Table 2** Differences in the clinicopathological characteristics in eligible omeprazole users and non-eligible omeprazole users

| Characteristics | Total | EOU | $P$ value |
|-----------------|-------|-----|-----------|
| Sex             |       |     |           |
| Male            | 90    | 46  | 44        | 0.59 |
| Female          | 35    | 16  | 19        |      |
| Age (yr)        |       |     |           |
| < 60            | 73    | 37  | 36        | 0.77 |
| ≥ 60            | 52    | 25  | 27        |      |
| BMI             |       |     |           |
| < 25            | 100   | 47  | 53        | 0.25 |
| ≥ 25            | 25    | 15  | 10        |      |
| Tumor size (cm) |       |     |           |
| ≤ 3             | 49    | 24  | 25        | 0.95 |
| 3-6             | 61    | 30  | 31        |      |
| ≥ 6             | 15    | 8   | 7         |      |
| Tumor grade     |       |     |           |
| 1               | 28    | 14  | 14        | 0.23 |
| 2               | 88    | 46  | 42        |      |
| 3               | 9     | 2   | 7         |      |
| cTNM            |       |     |           |
| II              | 39    | 22  | 17        | 0.31 |
| III             | 86    | 40  | 46        |      |
| CEA (ng/mL)     |       |     |           |
| < 5             | 62    | 28  | 34        | 0.47 |
| ≥ 5             | 58    | 30  | 28        |      |
| CA19-9 (U/mL)   |       |     |           |
| < 35            | 102   | 50  | 52        | 0.72 |
| ≥ 35            | 18    | 8   | 10        |      |
| TGR             |       |     |           |
| 0               | 39    | 23  | 16        | 0.25 |
| 1               | 15    | 8   | 7         |      |
| 2               | 20    | 12  | 8         |      |
| 3               | 24    | 9   | 15        |      |
| 4               | 27    | 10  | 17        |      |
| CRT efficacy    |       |     |           |
| Poor            | 74    | 43  | 31        | 0.02 |
| Good            | 51    | 19  | 32        |      |
| ypTNM           |       |     |           |
| ypT1c           | 25    | 9   | 16        | 0.34 |
| I               | 26    | 16  | 10        |      |
| II              | 40    | 20  | 20        |      |
| III             | 34    | 17  | 17        |      |
| Adjuvant CT     |       |     |           |
| No              | 21    | 9   | 12        | 0.5  |
| Yes             | 104   | 53  | 51        |      |
| Recurrence      |       |     |           |
| No              | 92    | 46  | 46        | 0.66 |
| Yes             | 33    | 16  | 17        |      |

EOU: Eligible OME users; non-EOU: Non-eligible OME users; BMI: Body mass index; TGR: Tumor regression grade; adjuvant CT: Adjuvant chemotherapy.

EOU: Eligible OME users; non-EOU: Non-eligible OME users; BMI: Body mass index; TGR: Tumor regression grade; adjuvant CT: Adjuvant chemotherapy.
The recurrence rate in EOG was 10.3% (3/29), which was significantly lower than 31.3% (30/96) in non-EOG ($P = 0.025$, OR = 0.25, 95%CI: 0.07-0.90; Table 3). The response rate of CRT efficacy in EOG was 55.2% (16/29), which was obviously increased compared with 36.5% (35/96) in non-EOG, with a marginally significant difference ($P = 0.072$, OR = 2.15, 95%CI: 0.93-5.00; Table 3). There was no significant difference in other clinicopathological features between the non-EOG and EOG groups (all $P > 0.05$, Table 3). Non-EOG received a total of 371 cycles of adjuvant chemotherapy, with a mean value of 3.9 ± 2.2. EOG received 108 cycles, and the mean value was 3.7 ± 2.6. The mean adjuvant chemotherapy cycles were not significantly different ($P = 0.77$) between the EOG and non-EOG groups.

At the end of the study, 96 (76.8%) patients were still alive. The patients who did not survive all died from tumor-related causes, and no patient died of PPI-related severe infection[36] during the CRT treatment. The mean DFS and mean OS of all patients was 62.9 mo ± 25.5 mo, 95%CI: 58.4-67.4) and 66.6 mo ± 21.8 mo, 95%CI: 62.8-70.5), respectively. The 3- and 5-year DFS rates of all patients were 81.6% and 75.1%, respectively. The 3- and 5-year OS rates of all patients were 85.6% and 78.8%, respectively.

A significant difference in DFS was noted between non-EOG and EOG patients ($P = 0.032$; Figure 2A, Table 4). In addition, a marginally significant difference in OS was also observed ($P = 0.092$; Figure 2B and Table 4). BMI, ypTNM and CRT efficacy were significantly associated with DFS ($P = 0.024$, $P < 0.005$ and $P = 0.031$, respectively; Table 4), whereas cTNM was a marginally significant factor of DFS ($P = 0.067$; Table 4). ypTNM was the only significant impact factor of OS ($P = 0.003$; Table 4), and BMI was a marginally significant factor of OS ($P = 0.05$; Table 4).

Cox proportional hazards model analysis

The univariate Cox analysis revealed that OME (non-EOG and EOG), BMI, CRT efficacy, and ypTNM were significantly associated with DFS ($P = 0.044$, 0.039, 0.036 and $P = 0.006$, respectively; Table 5). The cTNM was significantly associated with DFS ($P = 0.075$; Table 5), and BMI was marginally significantly associated with OS ($P = 0.069$; Table 5). ypTNM was a significant impact factor for OS ($P = 0.045$). No other clinicopathological features significantly associated with DFS and OS (all $P > 0.05$; Table 5).

Furthermore, multivariate Cox analysis demon-
Zhang JL et al. Omeprazole improves chemoradiotherapy efficacy

Figure 2  Disease-free survival curves (A) or OS curves (B) of non-omeprazole and omeprazole. EOG: Effective omeprazole.

Table 4  Univariate analysis of impact of various characteristics on patient survival

| Characteristics | n    | Mean (mo) ± SD | DFS | 3-yr* | 5-yr* | P value | Mean (mo) ± SD | OS | 3-yr* | 5-yr* | P value |
|-----------------|------|----------------|-----|-------|-------|---------|----------------|----|-------|-------|---------|
| Sex             |      |                |     |       |       |         |                |    |       |       |         |
| Male            | 90   | 61.8 ± 25.9    | 81.1% | 74.4% | 0.803 | 65.5 ± 22.2 | 84.4% | 79.9% | 0.855 |
| Female          | 35   | 65.6 ± 24.6    | 82.9% | 76.9% |       | 69.5 ± 20.1 | 88.6% | 79.8% |       |
| Age (yr)        |      |                |     |       |       |         |                |    |       |       |         |
| < 60            | 73   | 63.3 ± 26.3    | 80.1% | 71.1% | 0.533 | 68.4 ± 22.0 | 86.3% | 80.7% | 0.908 |
| ≥ 60            | 52   | 62.4 ± 24.6    | 82.7% | 80.7% |       | 64.2 ± 21.5 | 84.6% | 78.7% |       |
| Tumor size (cm) |      |                |     |       |       |         |                |    |       |       |         |
| < 3             | 48   | 62.5 ± 26.1    | 81.2% | 77.0% | 0.571 | 65.0 ± 22.4 | 83.3% | 79.2% | 0.962 |
| > 3             | 77   | 63.2 ± 25.3    | 81.8% | 74.0% |       | 67.7 ± 21.6 | 87.0% | 80.3% |       |
| BMI             |      |                |     |       |       |         |                |    |       |       |         |
| < 25            | 100  | 60.5 ± 26.8    | 77.0% | 69.9% | 0.024 | 65.3 ± 22.7 | 82.0% | 76.9% | 0.050 |
| ≥ 25            | 25   | 72.7 ± 16.6    | 96.0% | 96.0% |       | 72.1 ± 17.0 | 96.0% | 92.0% |       |
| Tumor grade     |      |                |     |       |       |         |                |    |       |       |         |
| 1               | 28   | 64.7 ± 28.0    | 78.6% | 75.0% | 0.852 | 69.4 ± 22.5 | 85.7% | 78.6% | 0.931 |
| 2, 3            | 97   | 62.4 ± 25.0    | 82.5% | 75.2% |       | 65.6 ± 21.7 | 85.6% | 80.2% |       |
| cTNM            |      |                |     |       |       |         |                |    |       |       |         |
| II              | 39   | 69.2 ± 23.2    | 87.2% | 84.6% | 0.067 | 71.9 ± 18.8 | 92.3% | 87.2% | 0.137 |
| III             | 86   | 60.0 ± 26.2    | 79.1% | 70.7% |       | 64.2 ± 22.8 | 82.6% | 76.4% |       |
| CEA (ng/mL)     |      |                |     |       |       |         |                |    |       |       |         |
| < 5             | 62   | 77.0 ± 4.1     | 69.2% | 69.2% | 0.789 | 79.6 ± 3.7  | 80.6% | 73.9% | 0.384 |
| ≥ 5             | 58   | 80.4 ± 4.3     | 82.8% | 74.0% |       | 86.1 ± 3.4  | 89.7% | 84.5% |       |
| CA19-9 (U/mL)   |      |                |     |       |       |         |                |    |       |       |         |
| < 35            | 102  | 81.3 ± 3.1     | 83.3% | 75.4% | 0.174 | 84.2 ± 2.7  | 86.3% | 80.2% | 0.597 |
| ≥ 35            | 18   | 68.1 ± 9.2     | 72.2% | 66.7% |       | 78.3 ± 7.8  | 77.8% | 72.2% |       |
| CRT efficacy    |      |                |     |       |       |         |                |    |       |       |         |
| Poor            | 74   | 60.7 ± 27.2    | 78.4% | 67.5% | 0.031 | 66.2 ± 23.2 | 83.8% | 75.6% | 0.144 |
| Good           | 51   | 66.1 ± 23.0    | 90.2% | 86.0% |       | 67.3 ± 19.9 | 88.2% | 86.1% |       |
| ypTNM          |      |                |     |       |       |         |                |    |       |       |         |
| ypT1c, I, II   | 91   | 66.1 ± 24.0    | 85.7% | 82.3% | 0.005 | 68.5 ± 20.1 | 89.0% | 84.4% | 0.041 |
| III            | 54   | 54.3 ± 28.0    | 70.6% | 55.6% |       | 61.6 ± 25.5 | 76.5% | 67.6% |       |
| Adjuvant CT     |      |                |     |       |       |         |                |    |       |       |         |
| No             | 21   | 60.2 ± 31.5    | 71.4% | 71.4% | 0.385 | 63.5 ± 26.5 | 76.2% | 66.3% | 0.229 |
| Yes            | 104  | 63.5 ± 24.3    | 83.7% | 75.8% |       | 67.3 ± 20.8 | 87.5% | 82.7% |       |
| OME            |      |                |     |       |       |         |                |    |       |       |         |
| Non- EOU       | 62   | 70.0 ± 25.8    | 85.5% | 75.6% | 0.658 | 73.9 ± 21.9 | 90.3% | 82.0% | 0.754 |
| EOU            | 63   | 55.9 ± 23.5    | 77.8% | 74.6% |       | 59.5 ± 19.5 | 82.5% | 77.6% |       |
| OME (200 mg)   |      |                |     |       |       |         |                |    |       |       |         |
| Non-EOG       | 96   | 62.0 ± 26.2    | 77.1% | 69.6% | 0.032 | 66.9 ± 24.1 | 82.3% | 76.9% | 0.092 |
| EOG            | 29   | 65.9 ± 13.3    | 96.6% | 46.7% |       | 65.8 ± 12.0 | 96.6% | 89.5% |       |

1Mean ± SD (mo); 2Three or 5 years survival rate. EOU: Eligible OME users; Non-EOU: Non-eligible OME users; EOG: Effective OME group; Non-EOG: Non-effective OME group; BMI: Body mass index; adjuvant CT: Adjuvant chemotherapy.
Table 5  Univariate Cox analysis of the impact of various characteristics on patient survival

| Characteristics | DFS HR   | 95%CI       | *P* value | OS HR  | 95%CI       | *P* value |
|-----------------|---------|-------------|-----------|--------|-------------|-----------|
| **Sex**         |         |             |           |        |             |           |
| Male vs Female  | 0.91    | 0.42-1.65   | 0.800     | 0.93   | 0.41-2.09   | 0.860     |
| **Age (yr)**    |         |             |           |        |             |           |
| < 60 vs ≥ 60    | 0.80    | 0.40-1.62   | 0.530     | 1.05   | 0.50-2.19   | 0.910     |
| < 25 vs ≥ 25    | 0.22    | 0.05-0.93   | 0.039     | 0.26   | 0.06-1.11   | 0.069     |
| Tumor size (cm) |         |             |           |        |             |           |
| ≤ 3 vs > 3      | 1.23    | 0.60-2.51   | 0.570     | 0.98   | 0.46-2.08   | 0.960     |
| Tumor grade     |         |             |           |        |             |           |
| 1 vs 2, 3       | 1.08    | 0.47-2.50   | 0.850     | 0.96   | 0.41-2.26   | 0.930     |
| cTNM II vs III  | 2.23    | 0.92-5.41   | 0.075     | 1.96   | 0.80-4.80   | 0.144     |
| CEA (ng/mL)     |         |             |           |        |             |           |
| ≤ 5 vs > 5      | 0.91    | 0.46-1.81   | 0.790     | 0.72   | 0.34-1.51   | 0.390     |
| CA199 (U/mL)    |         |             |           |        |             |           |
| < 35 vs ≥ 35    | 1.77    | 0.77-4.08   | 0.180     | 1.30   | 0.50-3.40   | 0.600     |
| CRT efficacy    |         |             |           |        |             |           |
| Poor vs good    | 0.43    | 0.19-0.95   | 0.036     | 0.55   | 0.24-1.24   | 0.150     |
| ypTNM ypCR, I, II vs III | 1.61 | 1.14-2.27 | 0.006 | 1.46 | 1.01-2.11 | 0.045 |
| Adjuvant CT     |         |             |           |        |             |           |
| Non vs yes EOU  | 0.69    | 0.30-1.60   | 0.390     | 0.60   | 0.25-1.40   | 0.240     |
| Non vs yes EOG  | 1.17    | 0.59-2.31   | 0.660     | 1.13   | 0.54-2.37   | 0.750     |
| Non vs yes     | 0.30    | 0.90-0.97   | 0.044     | 0.37   | 0.11-1.23   | 0.110     |

EOU: Eligible OME users; Non-EOU: Non-eligible OME users; EOG: Effective OME group; Non-EOG: Non-effective OME group; BMI: Body mass index; Adjuvant CT: Adjuvant chemotherapy.

strated that OME (non-EOG and EOG), BMI and ypTNM were independent and significant predictors of DFS (*P* = 0.048, HR = 0.30, 95%CI: 0.09-0.99, *P* = 0.038, HR = 0.22, 95%CI: 0.05-0.92 and *P* = 0.01, HR = 1.58, 95%CI: 1.12-2.22). ypTNM was also an independent and significant predictor of OS (*P* = 0.045, HR = 1.46, 95%CI: 1.01-2.11).

DISCUSSION

Neoadjuvant CRT could greatly improve the anus save rate and decrease local recurrence rate in advanced rectal cancer patients[2–4,37]. However, results addressing whether neoadjuvant CRT could improve survival are inconsistent[12,37]. The results of the present study showed that CRT efficacy is a significant clinicopathological factor associated with DFS (*P* = 0.031) and exhibits a favorable trend with OS (*P* = 0.144), indicating that CRT could decrease recurrence and potentially benefit OS. The results of the present study suggest that CRT efficacy is a significant clinicopathological factor associated with DFS, and this result is consistent with previous studies[2–4,37]. The present study results suggest that CRT has a potential benefit in OS, but is not a significant predictor. These results were consistent with the study by Sauer et al[37] but not with the study of Calogero Cammà et al[39]. As a potential chemotherapeutic agent[27,38–42], PPIs are safe to humans at high doses and with long-term treatment[37,38]. The mechanisms by which PPIs affect cancer include inhibiting V-ATPase activity[17,18], inducing apoptosis[21–23], promoting autophagy[24,25] and stimulating caspase-dependent cell death[35]. PPIs could sensitize chemoresistant tumors to cytotoxic drugs[26] and could improve the efficacy of T-cell-based cancer immunotherapy[27,28], suggesting that PPIs may improve cancer treatment efficacy. In the present study, we found a good response rate (50.8%) in the EOU group that was significantly increased compared with the non-EOU group (30.6%) (*P* = 0.02), suggesting that OME could enhance the sensitivity of rectal cancer to concurrent CRT. We noticed that after the OME dose cut-off was increased, the good response rate of CRT efficacy between EOG (55.2%) and non-EOG (36.5%) patients exhibited a marginally significant difference (*P* = 0.072). This result was likely caused by an elevated cut-off that resulted in a decreased EOG sample size, which would reduce statistical power. To the best of our knowledge, this study is the first to investigate the effect of PPIs on CRT efficacy.

Abnormal extracellular acidic pH could enhance the invasive capacity and metastatic behavior of cancer cells[43–46]. V-ATPase is involved in pH-dependent degradation of the extracellular matrix and promotion of tumor invasion and metastasis[26,47], suggesting that inhibition of V-ATPase may prevent metastasis. Consistent with these studies, the present study
results showed that the recurrence rate in EOG patients was 10.3%, which was significantly lower compared with 31.3% in non-EOG patients (P = 0.025). In addition, a significant difference in DFS was noted between non-EOG and EOG patients (P = 0.032), and a marginally significant difference in OS was noted (P = 0.092). Further multivariate Cox analysis demonstrated that OME (non-EOG and EOG) is an independent and significant predictor of DFS (P = 0.048). These results suggest that when administered as an adjuvant chemoradiotherapy drug, OME may exert synergistic effects with concurrent CRT to reduce tumor recurrence.

Whether the plasma concentration of the including criteria for dosage of OME in the present study could affect cancer cell vitality should be further discussed. The oral intake of 20 mg OME could produce a maximal plasma concentration of 2.5 mg/mL after two hours in patients.[46] The minimum OME dosage for the inclusion criteria in the present study was 40 mg intravenously administered, achieving a plasma concentration of 5 mg/mL. In in vitro studies, OME dissolved in normal saline at a concentration of 1 mg/mL induces apoptosis in B-cell cancers[22] and re-sensitizes drug-resistant cancer cell lines (22 melanomas, 2 colon adenocarcinomas, 2 breast cancers and 2 ovarian carcinomas) to cytotoxic drugs.[26] In in vivo studies, 0.4 mg/kg OME co-administered with dichloroacetate and tamoxifen exhibit a synergistically anti-proliferative effect on cholangiocarcinoma[49]. In addition, 2 mg/kg OME combined with dichloroacetate exhibited an antitumor effect on HT1080 fibrosarcoma cells inoculated in mice[30]. ESOM (2.5 mg/kg) reduced tumor growth in SCID mice engrafted with human melanoma[30]. In the present study, the minimum OME dose per kilogram of body weight was approximately 0.67 mg/kg (40 mg/60 kg), and the mean dose per kilogram of body weight was 3.6 mg/kg (217.2 mg/60.0 kg), which were higher than the least functional dosage reported above.[49]

BMI was significantly associated with DFS (P = 0.024) and was a marginally significant factor associated with OS (P = 0.05). Further multivariate Cox analysis demonstrated that BMI was an independent and significant predictor of DFS (P = 0.038), which was consistent with a previous study.[51]

Our study has several limitations. Although consecutive patients were included, it is a retrospective study. In addition, the patient sample of the study was relatively small. However, the effects of OME on CRT efficacy, tumor recurrence and patient survival were first investigated in the present study, which would be helpful for randomized and controlled trials in the future.

In conclusion, when used as an adjuvant drug in cancer treatment, omeprazole has a synergetic effect on improving CRT efficacy and decreasing rectal cancer recurrence.

**REFERENCES**

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2: 533-543. [PMID: 11905707 DOI: 10.1016/S1470-2045(01)00486-7]
2. Cammà C, Giunta M, Fiorica F, Pagliaro L, Craxì A, Cottone M. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. JAMA 2000; 284: 1008-1015. [PMID: 10944647]
3. Colorectal CCG. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304. [PMID: 11684209 DOI: 10.1016/S0140-6736(01)06409-1]
4. Valentini V, van Stiphout RG, Lammertin G, Gambaccorta MA, Barba MC, Bebenek M, Bonnetain F, Bosset JF, Buýko K, Cioni L, Gerard JP, Rödel C, Sainato A, Sauer R, Minsky BD, Collette L, Lambin P. Nomograms for predicting local recurrence, distant metastases, and overall survival for patients with locally advanced rectal cancer on the basis of European randomized clinical trials. J Clin Oncol 2011; 29: 3163-3172. [PMID: 21747092 DOI: 10.1200/JCO.2010.33.1595]
5. Nishi T, Furgac M. The vascular (H+-)-ATPases--nature’s most versatile proton pumps. Nat Rev Mol Cell Biol 2002; 3: 94-103. [PMID: 11816511 DOI: 10.1038/nrm729]
6. Sennoune SR, Luo D, Martinez-Zaguilán R. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem Biophys 2004; 40: 185-206. [PMID: 15054222 DOI: 10.1385/CBB:40:2:185]
7. De Millo A, Fais S. Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 2005; 1: 779-786. [PMID: 16556057 DOI: 10.2217/14796694.1.6.779]

**COMMENTS**

**Background**

Abnormal pH gradients of tumor microenvironment are involved in tumorigenesis, tumor progression and drug resistance. Vacular type H+-ATPases (V-ATPases) are proton pumps expressed on the membrane of endolysosomal organelles and the plasma membrane, which could modulate the tumor acidic microenvironment. Proton pump inhibitors (PPIs), such as omeprazole (OME) and esomeprazole, are used to relieve common side effects of chemotherapy, such as nausea and emesis. In addition to targeting the gastric acid pump, PPIs inhibit the activity of V-ATPases. Moreover, PPIs induce apoptosis in multiple cancer cells and promotes cancer cell autophagy. PPIs also sensitize chemo-resistant tumors to cytotoxic drugs and improve the efficacy of T-cell-based cancer immunotherapy. These study results suggest that application of PPIs may be helpful to improve cancer treatment. However, whether PPIs affect CRT efficacy, reduce tumor recurrence and improve survival in rectal cancer patients remain unclear.

**Research frontiers**

The present study investigates whether omeprazole used as an adjuvant drug in cancer treatment could improve cancer treatment efficacy.

**Innovations and breakthroughs**

In contrast with previous in vitro and in vivo studies, the present study clinically revealed that when used as an adjuvant drug in cancer treatment, omeprazole has synergetic effects on improving CRT efficacy and reducing rectal cancer recurrence.

**Applications**

When used as an adjuvant drug in cancer treatment, omeprazole has a synergetic effect on improving CRT efficacy and reducing rectal cancer recurrence and is helpful in improving cancer treatment efficacy.

**Peer-review**

Zhang et al retrospectively reviewed a series of 125 patients with rectal cancer and demonstrated that omeprazole users had better prognosis in term of response and recurrence rates and disease-free survival.
Omeprazole improves chemotherapeutic efficacy

8 Gerweck LE. Tumor pH: implications for treatment and novel drug design. *Semin Radiat Oncol* 1998; 8: 176-182 [PMID: 9834494]

9 Altan B, Chen Y, Schindler M, Simon SM. Defective acidification in human breast tumor cells and implications for chemotherapy. *J Exp Med* 1998; 187: 1583-1598 [PMID: 9584137]

Gerweck LE, Vijayappa S, Kozin S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. *Mol Cancer Ther* 2006; 5: 1275-1279 [PMID: 16731760 DOI: 10.1186/1535-7163. MCT-06-0024]

10 Raghunand N, Gillies RJ. pH and drug resistance in tumors. *Drug Resist Update* 2000; 3: 39-47 [PMID: 11498364 DOI: 10.1016/s0967-8012(00)000119]

11 Casey JR, Grinstein S, Orlovski J. Sensors and regulators of intracellular pH. *Nat Rev Mol Cell Biol* 2010; 11: 50-61 [PMID: 19997129 DOI: 10.1038/nrm2820]

Pérez-Sayáns M, Somoyo-Martin JM, Barros-Angueira F, Rey JM, García-Garcia V. V-ATPase inhibitors and implication in cancer treatment. *Cancer Treat Rev* 2009; 35: 707-713 [PMID: 19758758 DOI: 10.1016/j.ctrv.2009.08.003]

Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Matsuo K, Yamada Y, Kohno K. Elevated expression of vacuolar proton pump genes and cellular pH in cisplatin resistant. *Int J Cancer* 2001; 93: 869-874 [PMID: 11519050]

13 Torjoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K. Enhanced expression of the human vacular H(+)-ATPase c subunit gene (ATP6V1C) in response to anticancer agents. *J Biol Chem* 2002; 277: 36534-36543 [PMID: 12133827 DOI: 10.1074/jbc.M20605200]

14 Marquardt D, Center MS. Involvement of vacuolar H(+)-adenosine triphosphatase activity in multidrug resistance in HL60 cells. *J Natl Cancer Inst* 1991; 83: 1098-1102 [PMID: 1831509]

15 Mattson JP, Väähänen K, Wallmark B, Lorentzon P. Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases. *Biochim Biophys Acta* 1991; 1065: 261-268 [PMID: 1678211]

16 Moriaya Y, Patel V, Ueda I, Futai M. Evidence for a common binding site for omeprazole and N-ethylmaleimide in subunit A of chromaffin granule vacuolar-type H(+) ATPase. *Biochem Biophys Res Commun* 1993; 196: 699-706 [PMID: 8240346 DOI: 10.1016/bbrc.1993.2306]

18 Mizunushi K, Furukawa Y, Katano K, Abe K. Effect of omeprazole, an inhibitor of H(+)-K(+)-ATPase, on the bone resorption of human parathyroid cells. *Calcif Tissue Int* 1993; 51: 23-25 [PMID: 8023118]

19 Sabolić I, Brown D, Verbavatz JM, Kleinman J. H(+) ATPases of rectal cancer after preoperative radiochemotherapy. *Clin Cancer Res* 2012; 18: 65-70 [PMID: 9077718]

20 Andersson T, Andrén K, Cederberg C, Lagerström PO, Lundborg P, Skånberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. *Br J Clin Pharmacol* 1990; 29: 557-563 [PMID: 2350532]

21 McTavish D, Buckley MM, Heel RC. Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. *Drugs* 1991; 42: 138-170 [PMID: 1718683]

22 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. *Int J Colorectal Dis* 1997; 12: 19-23 [PMID: 912145]

23 De Milito A, Canese R, Marino ML, Borghi M, Iero M, Villa A, Venturet Gi, Lozupone F, Iessi E, Logozzi M, Della Mina P, Santinami K, Rohn K, Skånberg I. Pharmacokinetics and bioavailability of omeprazole after single and repeated oral administration in healthy subjects. *J Clin Oncol* 2010; 28: 207-219 [PMID: 19876915 DOI: 10.1002/jco.20509]

24 Lambert AA, Lam JO, Paik JJ, Ugarte-Gil C, Drummond MB, Crowell TA. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. *PloS One* 2015; 10: e0128004 [PMID: 26024824 DOI: 10.1371/journal.pone.0128004]

25 Sauer R, Liersch T, Merek S, Fiettkau R, Hohenberger W, Hess C, Becker H, Raab HR, Villanueva MT, Wittkekind H, Witzigmann H, Reißfelder C. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. *J Clin Oncol* 2012; 30: 1926-1933 [PMID: 22559255 DOI: 10.1200/JCO.2011.40.1836]

26 Fais S. Proton pump inhibitor-induced tumour cell death by induction of a detoxification mechanism. *J Intern Med* 2010; 267: 515-525 [PMID: 20433578 DOI: 10.1111/j.1365-2967.2010.02225.x]

27 Fais S, De Milito A, You H, Qin W. Targeting vacuolar H+-ATPases as a new strategy against cancer. *Cancer Res* 2007; 67: 10627-10630 [PMID: 18006801 DOI: 10.1158/0008-5472.CAN-07-1805]

28 De Milito A, Fais S. Proton pump inhibitors may reduce tumour...
Zhang JL et al. Omeprazole improves chemoradiotherapy efficacy

resistance. Expert Opin Pharmacother 2005; 6: 1049-1054 [PMID: 15957961 DOI: 10.1517/14656566.6.7.1049]

41 De Milito A, Marino ML, Fais S. A rationale for the use of proton pump inhibitors as antineoplastic agents. Curr Pharm Des 2012; 18: 1395-1406 [PMID: 22360553]

42 Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res 2010; 29: 44 [PMID: 20459683 DOI: 10.1186/1756-9966-29-44]

43 Martínez-Zaguilán R, Señor EA, Señor RE, Chu YW, Gillies RJ, Hendrix MJ. Acidic pH enhances the invasive behavior of human melanoma cells. Clin Exp Metastasis 1996; 14: 176-186 [PMID: 8605731]

44 Rofstad EK, Mathiesen B, Kindem K, Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006; 66: 6699-6707 [PMID: 16818644 DOI: 10.1158/0008-5472.CAN-06-0983]

45 Moellering RE, Black KC, Krishnamurty C, Baggett BK, Stafford P, Rain M, Gatenby RA, Gillies RJ. Acid treatment of melanoma cells selects for invasive phenotypes. Clin Exp Metastasis 2008; 25: 411-425 [PMID: 18301995 DOI: 10.1007/s10585-008-9145-7]

46 Smallbone K, Gavaghan DJ, Gatenby RA, Maini PK. The role of acidity in solid tumour growth and invasion. J Theor Biol 2005; 235: 476-484 [PMID: 15935166 DOI: 10.1016/j.jtbi.2005.02.001]

47 Cardone RA, Casavola V, Reshkin SJ. The role of disturbed pH dynamics and the Na+/H+ exchanger in metastasis. Nat Rev Cancer 2005; 5: 786-795 [PMID: 16175178 DOI: 10.1038/nrc1713]

48 Katagiri F, Inoue S, Itoh H, Takeyama M. Omeprazole raises somatostatin and motilin in human plasma. Biol Pharm Bull 2005; 28: 370-373 [PMID: 15684503]

49 Ishiguro T, Ishiguro R, Ishiguro M, Iwai S. Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report. Hepatogastroenterology 2012; 59: 994-996 [PMID: 22580646 DOI: 10.5754/hge10507]

50 Ishiguro T, Ishiguro M, Ishiguro R, Iwai S. Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors. Oncol Lett 2012; 3: 726-728 [PMID: 22740984 DOI: 10.3892/ol.2012.552]

51 Balakrishnan VS. Low BMI linked to worse colorectal cancer outcomes. Lancet Oncol 2015; 16: e593 [PMID: 26549590 DOI: 10.1016/S1470-2045(15)00475-1]
